• Approval

Eisai’s LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea

Tokyo, Septembe 02, 2018: Eisai Co., Ltd. announced that its South Korea subsidiary Eisai Korea Inc. received approval for the…